• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Traders Should Be Stopped Out of Biohaven Pharmaceutical

For now I would take a wait and see approach.
By BRUCE KAMICH
Nov 11, 2021 | 08:13 AM EST
Stocks quotes in this article: BHVN, PFE

In his first "Executive Decision" segment of Wednesday's Mad Money program, Jim Cramer spoke with Vlad Coric, CEO of Biohaven Pharmaceutical (BHVN) , the biotech.

Biohaven just announced a global partnership with Pfizer (PFE) to bring its migraine treatment, Nurtec ODT, to patients outside the U.S. Coric said in the deal, Biohaven retains the U.S. rights to Nurtec, but leverages Pfizer's global presence to commercialize the drug around the globe.

Nurtec remains the only drug approved for both the treatment and prevention of migraine. There is no other therapy that does what Nurtec does, Coric noted.

Coric said the company has a broad pipeline of neuroscience-based drugs in development and it will be using the proceeds from the Pfizer deal to double-down on the efforts.

Let's check and see what the charts are up to after their earnings numbers the other day.

In this daily bar chart of BHVN, below, we can see that prices made a small double top pattern in October and early November. Prices gapped lower the other day breaking below the rising 50-day moving average line.

Trading volume increased sharply and the On-Balance-Volume (OBV) line made a new low for the move down. A weak OBV line tells us that sellers of a stock are being more aggressive. The OBV line peaked in June on BHVN.

The Moving Average Convergence Divergence (MACD) oscillator has been making lower highs since July and is close to breaking below the zero line for an outright sell signal.

In this weekly Japanese candlestick chart of BHVN, below, we can see two small upper shadows around $150 and that was a tell in hindsight. This week's long red (bearish) candle sets the tone for further weakness. Prices are still above the rising 40-week moving average line but that is not much consolation.

The weekly OBV line looks toppy and the MACD oscillator has crossed to the downside for a take profits sell signal.

In this daily Point and Figure chart of BHVN, below, we can see a potential downside price target in the $74 area. Ouch.

In this weekly Point and Figure chart of BHVN, below, we can see a $106 price target at this point in time.

Bottom line strategy: In our September 10 review of BHVN we wrote that "Continue to hold longs. Raise stops to $125 from $115. The $155-$163 area is our first price target with the $181-$188 area after that."

Unfortunately prices stopped rising at $151 so I do not know if traders took profits or not. The gap lower should have stopped traders out around $125 or lower. Now I would take a wait and see what happens stance with BHVN. Maybe it rebases above $110 or perhaps it sinks further towards one of our Point and Figure targets.

We're holding a Veterans Day Sale for our Action Alerts PLUS investment club. Get in on the conversation and get the latest investment ideas and trading strategies. For 48 hours, we're offering 30% off with this special sale. Click here and save $150.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Earnings | Investing | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals | Mad Money | Executive Interview

More from Investing

Will Reaction to Fed Give Market a Needed Washout?

James "Rev Shark" DePorre
Sep 20, 2023 4:16 PM EDT

As Fed 'proceeds carefully,' the market could use a good flush to set it up for a bounce.

Powell Tries Hard to Hide His Dovish Side

Peter Tchir
Sep 20, 2023 3:47 PM EDT

Expect no Fed rate cuts, but for rates to hold higher for longer.

The Housing Market Is Turning in an Ugly Direction

Bret Jensen
Sep 20, 2023 2:15 PM EDT

2024 could be a brutal for the real estate sector.

Investors Should Brace for a UAW Win

Bob Lang
Sep 20, 2023 1:15 PM EDT

Here's what to look out for as the auto strike continues.

I Just Can't Give Boeing the All-Clear Yet

Stephen Guilfoyle
Sep 20, 2023 12:17 PM EDT

This defense and aerospace stock looks brighter than its competitors, but it's still a tough jet to fly.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:41 PM EDT CHRIS VERSACE

    Latest AAP Podcast With Helene Meisler!

    Listen in as the Action Alerts PLUS podcast talks ...
  • 09:07 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Most Common and Costly Mistake in Investing
  • 10:23 AM EDT PETER TCHIR

    August CPI, Sticky Inflation and the Fed

    CPI, in grand scheme of things, was a non-event......
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login